Morning Watchlist: Sunday Edition
A quick note from Behind the Markets
Sunday is a good day to ignore the index and study the plumbing.
A private-equity firm is taking a newly public insurance marketplace private — at a price below its IPO. Japan's government is now publicly backing a rate hike, after the U.S. and Japan already intervened jointly in the currency market. And the strongest small-cap advantage is becoming less about a clever product than the ability to turn revenue into cash while the rules keep changing.
Wall Street will call these isolated events. They point to one market: capital is becoming more selective. Not more scarce — selective. Money is still available in enormous quantity, but it is asking harder questions before it moves, and it is increasingly willing to pay for control rather than participation.
Four pieces of plumbing today.
1) The Public Market Is Losing Its Boring Winners
Thoma Bravo agreed on Thursday to take Accelerant private — an all-cash deal at $20.25 per share, an enterprise value above $4 billion, and a 49% premium to the prior close. The company listed on the NYSE only in July of last year.
That $20.25 is below Accelerant's $21 IPO price. The stock had fallen roughly 52% from its $28.50 first-day level to $13.59 before the offer arrived. So the 49% premium is a premium to a beaten-down quote — not to intrinsic value, and certainly not to what public shareholders paid. Anyone who bought this business at the IPO is being taken out at a loss, thirteen months later, and told it's a 49% win. RBC's analyst called it "a good outcome, considering the extreme volatility in the market and the disconnect between the company's fundamentals and the share price." Note the framing: a good outcome given the disconnect. Not a good return.
Now the part that tells you what the asset is actually worth. Altamont Capital Partners, which controls about 82% of the voting rights, and the founders are not cashing out — they're rolling their equity forward alongside Thoma Bravo. The people with the most information are staying in. The public shareholders are the ones being handed cash.
And the business is accelerating. Second-quarter revenue reached $356.9 million against $219.1 million a year earlier. Net income was $80.0 million versus $13.1 million. Adjusted EBITDA hit $93.1 million at a 31% margin. Exchange Written Premium grew 23% to $1.32 billion, with trailing-twelve-month premium of $4.6 billion. This is a company going private while inflecting — which is precisely why the insiders are rolling and the outsiders are being paid off.
So the real lesson isn't "study boring compounders before a buyer takes them." It's sharper than that: when a controlling holder has 82% of the votes, public shareholders are passengers, not owners. Look for vertical marketplaces and specialty service businesses with high retention, low customer concentration, and a product embedded in a regulated or mission-critical workflow. But add a fourth filter: who controls the vote, and what happens to me if they decide to leave? A dual-class structure with a supermajority holder means your upside can be capped by someone else's timeline.
Two mechanics worth noting for anyone who owns it now: the deal isn't expected to close until the first half of 2027, and shareholders receive a ticking fee accruing at 6% per year if insurance regulatory approvals delay it. Accelerant also cancelled its scheduled earnings call.
Bottom line: A take-private deal is a valuation signal — but check whose valuation. Study the boring compounders, and read the share structure before you assume the upside belongs to you.
2) The Dollar's Next Move Runs Through Japan
The BOJ raised its rate to 1.0% in June — the highest level since September 1995 — and held there in July on an 8-1 vote, with board member Hajime Takata dissenting in favor of 1.25%. The July summary of opinions flagged growing risks of accelerating inflation, with one member arguing the pace of hikes could quicken. And Japanese producer prices rose 7.2% year over year in July. This is no longer a deflationary economy tolerating a zero rate; it's an economy with real inflation and a central bank running behind it.
Then the two developments that pulled expectations forward. First, the U.S. and Japanese governments have already intervened jointly in the currency market — Bank of America revised its year-end yen forecast to 149 per dollar from 152 on the back of it, and wrote that the intervention "raised the stakes for a successful defense of the yen, which likely requires follow-through from macroeconomic policies: specifically, faster rate hikes." Second, on Thursday, reports indicated Prime Minister Takaichi's government is supportive of a near-term hike, with the next move likely in September or October. When a government publicly blesses tightening, the central bank's political cover changes.
The yen was still trading near 159 per dollar — right at the edge of the 158–160 zone where authorities have intervened before — so the pressure hasn't resolved. Wide rate differentials, fiscal concerns, and elevated energy and import costs are all still weighing.
For U.S. investors, the point isn't to forecast the next tick. It's that the world's cheapest funding currency is being repriced, and that travels. A stronger yen and a narrowing rate differential ripple through crowded carry trades, multinational earnings translation, and any small company with meaningful foreign revenue or imported input costs. Currency isn't a macro footnote; it's a margin variable hiding inside the income statement — and it moves before any analyst revises an estimate.
Currency is a lens rather than a position. The useful exercise this weekend: for every holding you own, know whether it has exposure to Japanese markets and whether a 6% move in the yen or a 200-basis-point shift in global funding costs helps it, hurts it, or does nothing. Most investors cannot answer that for a single name they own.
Bottom line: Watch Japan because funding conditions travel. The next dollar move can change which companies look cheap — and which only looked cheap in translation.
3) The New Small-Cap Edge Is Cash Conversion
The easy version of small-cap investing is to find a large market and pay for a future winner. The durable version is to find a business that collects cash before it has to spend the next dollar. In a world of tariffs, elevated term premiums, and selective credit, that difference decides who keeps investing and who raises capital at the worst possible moment.
Start with the operating cycle, and ask four questions:
Are receivables expanding faster than sales? If customers are taking longer to pay, you're financing them.
Is inventory becoming a parking lot? Rising inventory days ahead of a tariff deadline can be prudence — or it can be product nobody wants.
Does management call adjusted EBITDA "cash" while working capital consumes it? EBITDA is an opinion about profit. Operating cash flow is a bank statement.
Would this company have to dilute you to fund its own growth plan? That's the question that actually costs people money.
Here's the discipline in practice, using a company from the next section. Exponent — a business with 28% EBITDA margins and no factories — generated only $29.9 million of operating cash flow in its second quarter, while its cash balance fell from $221.9 million to $66.6 million. Nothing is wrong: the gap is share repurchases, $146.1 million of them in six months, and management expects over $100 million of free cash flow in the back half. But if you had read only the EBITDA margin, you would have missed a $155 million swing in the cash position, and you would not have known to ask where it went. The margin told you the business is good. Only the cash statement told you what management did with it.
The market may forgive a temporary margin miss. It is far less forgiving when a company needs a dilutive financing to fund growth that was supposed to be self-financing.
Bottom line: Revenue is a promise. Cash conversion is evidence. For small caps, evidence is becoming the moat.
4) Industrial Policy Is Creating a New Audit Industry
Everything we've covered for two weeks — green-steel funding frameworks, tariff deadlines, polysilicon price floors, cross-border procurement — shares a hidden requirement. Somebody has to verify. Origin. Emissions. Compliance. Chain of custody. Standards. When the rules change, a company can't simply assert that its material came from the right place and met the right specification; it has to prove it, to a customer, a regulator, or a lender who won't finance the shipment otherwise.
That's an opportunity set sitting beyond the manufacturers: testing laboratories, certification firms, engineering consultancies, industrial software, and the data providers that make a complicated supply chain financeable. It's a vertical services-and-software angle, not another generic reshoring pitch.
One honest structural note before the name: the largest pure-play testing and certification businesses in the world — SGS, Bureau Veritas, Intertek, DNV — are not U.S.-listed, which can be a real limitation. The accessible version of the theme is engineering and scientific consulting.
The Stock: Exponent (NASDAQ: EXPO)
Exponent is a science and engineering consultancy that gets paid to determine what happened and whether something meets a standard. Its work splits between reactive failure analysis — a product broke, a structure failed, a chemical caused a dispute, and somebody needs a defensible technical answer — and proactive work: regulatory support, utility infrastructure risk assessment, and user research on AI-enabled products. It is the closest listed proxy to "somebody has to verify," and it is asset-light by construction: the inventory is PhDs.
The second quarter, reported July 30, was strong. Revenue rose 21% to $171.6 million, well ahead of the roughly $147.5 million expected; net revenues before reimbursements grew 12% to $148.9 million. EPS of $0.60 beat the $0.56 consensus and rose 15%. EBITDA reached $42.7 million at a 28.7% margin, up from 27.8%. The Engineering and Other Scientific segment — 85% of net revenue — grew 13% on user research and utility infrastructure work, while Environmental and Health grew 9% on chemical health-impact evaluations. Realized billing rates rose about 4%. Management raised full-year guidance to 9–10% net revenue growth with EBITDA margins of 27.8–28.1%, added $50 million to the buyback authorization, and declared a $0.31 quarterly dividend.
Now the other side, and there are three items worth your attention.
One: a single study was 4% of net revenues — a large AI user-research engagement that came in at double management's own 2% expectation. That's a wonderful quarter and a lumpy revenue base. Strip it out and the growth rate looks materially more ordinary, so don't extrapolate this quarter's rate.
Two: the cash story is the one from section three. Operating cash flow of $29.9 million against a $155 million decline in the cash balance, driven by buybacks. Management's own filing notes the repurchase authorization is capacity rather than a commitment — exactly the distinction we apply to every buyback announcement — and the CFO acknowledged the repurchases reduced interest income. The promised $100 million-plus of second-half free cash flow is a forecast, not a receipt.
Three: valuation and momentum are not on your side. This trades at a premium multiple that limits the margin for error, technical trend signals are weak, at least one screening service flags multiple warning signs, and the CEO sold shares in July. Execution risk here is specific and mundane: utilization rates and technical staffing. A consultancy that can't keep its experts busy loses margin fast.
Verdict: the right business model for the theme, in a quarter flattered by one large study, with the buyback doing some of the per-share work. Watchlist, on a pullback — which management has effectively told you they're waiting for too, having said they'll be more active in repurchases when the stock falls.
Bottom line: Regulation creates paperwork before it creates winners. The companies that turn compliance into a repeatable workflow can earn recurring revenue from every new rule — just make sure you're paying for the workflow and not for one unusually large project.
Before You Go
Capital is moving toward businesses that can prove what they do, collect what they earn, and own a bottleneck the customer can't easily replace.
Accelerant proved it the hard way: a business inflecting, taken private below its IPO price, with the controlling holder rolling forward and the public shareholders paid off. Japan is proving it in the funding markets, where the cheapest money in the world is quietly being repriced with a government's blessing. And the cash-conversion question is proving it one balance sheet at a time — a 28% margin that still saw its cash pile fall by $155 million, for reasons that were perfectly fine but entirely invisible in the margin.
That's where independent investors still have an edge. You don't need to outspend Wall Street. You need to notice what it's too busy to model — and to read the third page of the release, where the answers usually are.
Found this helpful? Share it with others.
Written by Behind the Markets